Skip to main content
Article thumbnail
Location of Repository

Potential of liraglutide in the treatment of patients with type 2 diabetes

By Carolyn F Deacon

Abstract

Liraglutide is a long-acting analog of GLP-1, being developed by Novo Nordisk and currently undergoing regulatory review for the treatment of type 2 diabetes. Upon injection, liraglutide binds non-covalently to albumin, giving it a pharmacokinetic profile suitable for once-daily administration. In clinical trials of up to 1 year duration, liraglutide has been demonstrated to have beneficial effects on islet cell function, leading to improvements in glycemic control. Both fasting and postprandial glucose concentrations are lowered, and are associated with lasting reductions in HbA1c levels. Liraglutide is effective as monotherapy and in combination therapy with oral antidiabetic drugs, and reduces HbA1c by up to ∼1.5% from baseline (8.2%–8.4%). Because of the glucose-dependency of its action, there is a low incidence of hypoglycemia. Liraglutide is associated with body weight loss, and reductions in systolic blood pressure have been observed throughout the clinical trials. The most common adverse events reported with liraglutide are gastrointestinal (nausea, vomiting and diarrhea). These tend to be most pronounced during the initial period of therapy and decline with time. Further clinical experience with liraglutide will reveal its long-term durability, safety and efficacy

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2672437
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2008). [website]. Liraglutide press release,
    2. 11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig.
    3. An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide.
    4. (2002). Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes.
    5. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects.
    6. (2008). Capital markets day: liraglutide [accessed 26
    7. (1998). Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity.
    8. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes.
    9. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.
    10. (2008). Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept.
    11. (1998). Effect of intensive blood-glucose control with metformin on complications
    12. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
    13. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab.
    14. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension.
    15. Effect of the GLP-1 analogue liraglutide on glycaemic control and weight reduction in patients on metformin and rosiglitazone: a randomised double-blind placebo controlled trial.
    16. (2005). Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care.
    17. (2004). Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care.
    18. (2008). Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin.
    19. (2005). Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. Diabet Med.
    20. (2007). Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Diabetes Care.
    21. Effects of the once-daily human GLP-1 analogue liraglutide on appetite and energy intake
    22. (2009). Effi cacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). Diabetes Care.
    23. Effi cacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Horm Metab Res.
    24. (2008). Exenatide and pancreatitis: an update. Expert Opin Drug Saf.
    25. Exenatide and rare adverse events.
    26. (2008). Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin.
    27. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, openlabel, non-inferiority study.
    28. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular fi ltration in anaesthetised pigs.
    29. (2006). Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes.
    30. GLP-1 derivative liraglutide in rats with beta-cell defi ciencies: infl uence of metabolic state on beta-cell mass dynamics.
    31. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.
    32. (1996). Glucagon-like peptide 1 undergoes differential tissue-specifi c metabolism in the anesthetized pig.
    33. (2001). Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care.
    34. (1997). Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care.
    35. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
    36. (2004). Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagonlike peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care.
    37. Increased risk of acute pancreatitis observed in patients with type 2 diabetes.
    38. (2008). Incretin mimetics and enhancers: clinical applications. Aust Prescr.
    39. (1998). Infl uence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care.
    40. (1998). Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications
    41. Liraglutide added to a sulphonylurea (SU) offers signifi cantly better glycaemic control and favourable weight change compared with rosiglitazone and
    42. Liraglutide induces cell proliferation and protects from interleukin-1 beta-induced β-cell apoptosis in human islets.
    43. (2008). Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet.
    44. Liraglutide, a human GLP-1 analogue, reduces systolic blood pressure in subjects with type 2 diabetes.
    45. (2007). Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy signifi cantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care.
    46. Liraglutide, a once daily human GLP-1 analog, added to a sulphofl urea (SU) offers signifi cantly better glycemic control and favorable weight change compared with rosiglitazone and SU combination therapy in subjects with type 2 diabetes.
    47. (2008). Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and argininestimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med.
    48. Liraglutide, a once-daily human GLP-1 analogue, in type 2 diabetes provides similar glycaemic control with reduced bodyweight compared with glimepiride when added to metformin
    49. (2008). Liraglutide: superior glycemic control vs exenatide when added to metformin and/or SU in type 2 diabetes.
    50. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care.
    51. Metabolism and excretion of the once-daily human GLP-1 analogue liraglutide in healthy subject and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase.
    52. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.
    53. No impairment of hypoglycemia counterregulation via glucagon with NN2211, a GLP-1 derivative, in subjects with type 2 diabetes.
    54. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients.
    55. One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
    56. (2008). Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide. Diabetes Obes Metab.
    57. Pharmacokinetic modelling of the once-daily human glucagon.like peptide-1 analogue, liraglutide, in healthy volunteers and comparison to exenatide.
    58. pharmacokinetics and pharmacodynamics of the oncedaily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study.
    59. Pharmacokinetics of the long-acting human GLP-1 analogue liraglutide in subjects with renal impairment.
    60. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration.
    61. (2008). Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab.
    62. Signifi cantly better glycaemic control/weight reduction with human GLP-1 analogue liraglutide, than with insulin glargine: all as add-on to metformin + sulphonylurea in type 2 diabetes.
    63. Signifi cantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with insulin glargine: all as add-on to metformin and a sulfonylurea in type 2 diabetes.
    64. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.
    65. Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways.
    66. (2007). Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes.
    67. The dipeptidyl peptidase-4 inhibitor vildagliptin increases portal concentrations of active GLP-1 to a greater extent than the peripheral concentrations.
    68. (2004). The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care.
    69. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose.
    70. (2009). The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol.
    71. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.
    72. The long-acting glucagonlike peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro.
    73. The once daily human GLP-1 analogue liraglutide decreases postprandial hunger and energy intake.
    74. The once-daily human GLP-1 analogue liraglutide improves both absolute- and baselinecorrected postprandial glucose levels.
    75. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.
    76. (2007). The physiology of glucagon-like peptide 1. Physiol Rev.
    77. The reduction in bodyweight with liraglutide, a once-daily human GLP-1 analogue for type 2 diabetes, primarily comes from fat tissue and the fat tissue lost is predominantly visceral fat.
    78. (1997). Tissue-specifi c expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard.
    79. Vildagliptin improves alpha cell glucose sensing in patients with type 2 diabetes.
    80. Vildagliptin signifi cantly decreases blood pressure (BP) in hypertensive patients (pts) with type 2 diabetes (T2DM) compared with metformin.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.